M3, Inc.

M3, Inc.

10.36
USD
+0.19
(+1.89%)
7.36BMarket Cap
Nov 04Next Earn
M3, Inc.
OTC:MTHRF
(OTC Markets)

Recent

price

10.36

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
23.3
30.13
40.96
57.68
79.4
99.92
120.7
145.88
174.53
193.05
249.31
306.67
340
351.85
419.57
519.03
- -
Revenue per Share
5.55
7.11
8.82
13.2
15.09
19.33
24.72
27.99
30.22
31.89
55.73
94.06
72.22
66.68
59.62
72.53
- -
Basic EPS, GAAP
4.74
7.96
8.75
13.09
13.28
17.6
24.38
21.72
25.32
35.3
65.77
72.03
76.24
74.72
62.96
- -
- -
Free Cash Flow per Basic Share
1.5
2.07
2.08
2.99
3.25
4
4.5
5
5.18
6.68
8.5
12
16
18.99
21
- -
- -
Dividend per Share
21.26
26.83
35.26
56.64
69.9
84.81
103.57
127.34
152.39
244.79
294.4
379.82
445.75
518.27
557.32
611.63
- -
Book Value per Share
17.29
17.95
25.11
32.73
39.52
47.29
36.07
48.96
64.62
139.63
182.61
257.7
280.71
301.66
253.18
277.08
- -
Tangible Book Value per Share
629
632
635
637
647
647
647
648
648
678
679
679
679
679
679
677
674
Basic Weighted Avg Shares
14,647
19,041
26,008
36,759
51,346
64,660
78,143
94,471
113,059
130,973
169,198
208,159
230,818
238,883
284,900
351,363
- -
Sales/Revenue/Turnover
54.81
40.17
35.74
34.14
31.21
30.85
31.76
29.06
27.15
26.3
34.28
31.81
30.55
26.38
21.16
20.23
- -
Operating Margin (%)
375
557
613
375
671
867
939
1,161
1,391
4,493
5,736
6,274
7,434
8,878
12,205
- -
- -
Depreciation Expense
3,487
4,493
5,599
8,415
9,759
12,508
16,004
18,127
19,577
21,635
37,822
63,845
49,028
45,271
40,484
49,100
- -
Net Income, GAAP
41.09
39.9
38.42
36.25
35.53
32.37
32.14
30.02
31.01
30.21
29.29
31.27
30.05
29.48
31.56
29.14
- -
Effective Tax Rate (%)
23.81
23.6
21.53
22.89
19.01
19.34
20.48
19.19
17.32
16.52
22.35
30.67
21.24
18.95
14.21
13.97
- -
Profit Margin (%)
9,649
9,724
11,767
17,309
20,057
23,875
21,267
29,041
35,987
83,401
113,801
141,658
143,891
173,570
161,311
173,028
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
94
16,483
21,342
28,983
- -
LT Debt
13,708
17,481
23,426
37,461
46,510
56,562
69,510
85,168
102,276
171,601
207,260
263,953
309,518
366,701
412,799
446,649
- -
Total Equity
24.96
26.25
25.25
26.55
23.01
24.55
25.2
23.36
21.42
16.63
20.48
26.4
16.94
12.73
10.26
11.12
- -
Return on Invested Capital (%)
27.38
27.82
26.13
26.18
21.66
22.56
24.02
22.07
19.01
13.98
18.23
26.15
16.08
12.17
9.03
9.79
- -
Return on Capital (%)
28.69
29.57
28.4
28.51
23.85
24.99
26.25
24.24
21.61
16.34
20.67
27.9
17.5
13.83
11.09
12.48
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
3,409
4,166
- -
LT Borrowings
29,143
28,983
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
678
667
667
Market Capitalization
1,375,109
1,167,652
906,014

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
248,431
273,035
- -
Cash, Cash Equivalents & STI
168,574
187,065
- -
Accounts Receivable, Net
67,506
74,619
- -
Inventories
- -
- -
- -
Total Current Liabilities
91,973
100,007
- -
Payables & Accruals
- -
- -
- -
ST Debt
3,409
4,166
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.79%
16.77%
8.2%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
18.32%
9.73%
21.28%
Sales/Revenue/Turnover
18.65%
16%
23.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
284,900
2026
- -
- -
- -
- -
351,363
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
59.62
2026
- -
- -
- -
- -
72.53
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
21
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
M3, Inc. engages in the provision of medical-related services primarily through internet-based platforms targeting physicians and healthcare professionals. The company operates through six main business segments: Medical Platform, Evidence Solution, Career Solution, Site Solution, Overseas, and Other Emerging Businesses. Its Medical Platform segment includes m3.com, a members-only site offering medical information and tools; MR-kun, delivering daily medical updates; QOL-kun, a marketing support service for doctors; AskDoctors, a consumer service for health questions; and region-specific medical professional sites such as MDLinx in the U.S. and Doctors.net.uk in the U.K. The Evidence Solution segment supports clinical trials management and research operations. The Career Solution segment offers recruitment, job advertisement, and human resources services for medical professionals in Japan. The Site Solution segment provides management support and consulting services to medical institutions, including home-visit nursing and electronic medical records solutions. The Overseas segment extends marketing support, research, clinical trial support, and human resource services across the U.S., U.K., China, South Korea, India, France, Germany, and Spain. Founded in 2000 and headquartered in Tokyo, Japan, M3, Inc. serves pharmaceutical companies, medical device manufacturers, healthcare professionals, and medical institutions globally. Recent major company developments include multiple strategic acquisitions and business expansions: M3 acquired Kantar’s specialist healthcare research businesses to expand its global healthcare panel and research capability; it acquired Michael Allen Company in the U.S. to strengthen pharmaceutical relationships; it purchased the medical accounting and electronic health record (EHR) business from Canon Medical Systems to accelerate digital transformation in clinics through its M3 DigiKar cloud EHR system; it launched the Clinic Succession Platform to support continuity of medical institutions; it initiated an AI medical image diagnostics platform in collaboration with NOBORI; and it expanded into COVID-19 remote image diagnosis support with Alibaba and St. Marianna University School of Medicine Hospital. Additionally, M3 consolidated subsidiaries such as DailyRounds, entering medical education services in India, and CUC, Inc., which was newly listed on the Tokyo Stock Exchange Growth Market. The company also continues to advance consumer healthcare platforms, evidenced by ongoing development of LINE Healthcare remote consultation services. M3’s share repurchase program was announced recently, reflecting financial strength and shareholder returns initiatives. M3, Inc. maintains a significant presence across Japan, the U.S., Europe, India, and several Asian markets, operating platforms and services that connect healthcare professionals with pharmaceutical companies and provide comprehensive medical-related information, clinical trial support, career services, institutional management, and healthcare research solutions.

Company News